tiprankstipranks
Trending News
More News >
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
US Market
Advertisement

Cidara Therapeutics (CDTX) Stock Forecast & Price Target

Compare
771 Followers
See the Price Targets and Ratings of:

CDTX Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Cidara
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CDTX Stock 12 Month Forecast

Average Price Target

$59.17
▲(14.89%Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $59.17 with a high forecast of $75.00 and a low forecast of $45.00. The average price target represents a 14.89% change from the last price of $51.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","76":"$76","25.75":"$25.8","42.5":"$42.5","59.25":"$59.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$59.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,25.75,42.5,59.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.03,51.027692307692305,53.02538461538462,55.02307692307692,57.02076923076923,59.01846153846154,61.01615384615385,63.01384615384615,65.01153846153846,67.00923076923077,69.00692307692307,71.00461538461539,73.0023076923077,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.03,49.81,50.59,51.370000000000005,52.15,52.93,53.71,54.49,55.27,56.050000000000004,56.83,57.61,58.39,{"y":59.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.03,48.72,48.410000000000004,48.1,47.79,47.480000000000004,47.17,46.86,46.55,46.24,45.93,45.62,45.31,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.36,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.89,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$75.00Average Price Target$59.17Lowest Price Target$45.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CDTX
TipRanks AITipRanks
Not Ranked
TipRanks
$57
Hold
10.68%
Upside
Reiterated
07/15/25
Cidara Therapeutics' overall stock score is primarily impacted by its challenging financial performance and speculative valuation. Technical indicators show bullish momentum but are countered by overbought conditions. The earnings call and corporate events provide some optimism with progress in drug development and improved financial positioning. However, significant risks due to financial health must be addressed.
Guggenheim
$68$69
Buy
33.98%
Upside
Reiterated
07/08/25
Cidara Therapeutics price target raised to $69 from $68 at GuggenheimCidara Therapeutics price target raised to $69 from $68 at Guggenheim
Citizens JMP Analyst forecast on CDTX
Roy BuchananCitizens JMP
Citizens JMP
$47$59
Buy
14.56%
Upside
Reiterated
06/30/25
Citizens JMP Remains a Buy on Cidara Therapeutics (CDTX)
Needham
$36$54
Buy
4.85%
Upside
Reiterated
06/23/25
Analysts Are Bullish on Top Healthcare Stocks: Cidara Therapeutics (CDTX), Sana Biotechnology (SANA)
WBB Securities Analyst forecast on CDTX
Stephen BrozakWBB Securities
WBB Securities
$45
Buy
-12.62%
Downside
Reiterated
06/23/25
Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX), Hims & Hers Health (NYSE: HIMS) and Biomea Fusion (NASDAQ: BMEA)
H.C. Wainwright Analyst forecast on CDTX
Sara NikH.C. Wainwright
H.C. Wainwright
$41$53
Buy
2.91%
Upside
Reiterated
06/23/25
Cidara Therapeutics price target raised to $53 from $41 at H.C. WainwrightCidara Therapeutics price target raised to $53 from $41 at H.C. Wainwright
RBC Capital Analyst forecast on CDTX
Brian AbrahamsRBC Capital
RBC Capital
$35$75
Buy
45.63%
Upside
Reiterated
06/23/25
Cidara Therapeutics price target raised to $75 from $35 at RBC CapitalCidara Therapeutics price target raised to $75 from $35 at RBC Capital
Cantor Fitzgerald Analyst forecast on CDTX
Eric Schmidt FCACantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
06/10/25
Cidara Therapeutics (CDTX) Receives a Buy from Cantor Fitzgerald
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CDTX
TipRanks AITipRanks
Not Ranked
TipRanks
$57
Hold
10.68%
Upside
Reiterated
07/15/25
Cidara Therapeutics' overall stock score is primarily impacted by its challenging financial performance and speculative valuation. Technical indicators show bullish momentum but are countered by overbought conditions. The earnings call and corporate events provide some optimism with progress in drug development and improved financial positioning. However, significant risks due to financial health must be addressed.
Guggenheim
$68$69
Buy
33.98%
Upside
Reiterated
07/08/25
Cidara Therapeutics price target raised to $69 from $68 at GuggenheimCidara Therapeutics price target raised to $69 from $68 at Guggenheim
Citizens JMP Analyst forecast on CDTX
Roy BuchananCitizens JMP
Citizens JMP
$47$59
Buy
14.56%
Upside
Reiterated
06/30/25
Citizens JMP Remains a Buy on Cidara Therapeutics (CDTX)
Needham
$36$54
Buy
4.85%
Upside
Reiterated
06/23/25
Analysts Are Bullish on Top Healthcare Stocks: Cidara Therapeutics (CDTX), Sana Biotechnology (SANA)
WBB Securities Analyst forecast on CDTX
Stephen BrozakWBB Securities
WBB Securities
$45
Buy
-12.62%
Downside
Reiterated
06/23/25
Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX), Hims & Hers Health (NYSE: HIMS) and Biomea Fusion (NASDAQ: BMEA)
H.C. Wainwright Analyst forecast on CDTX
Sara NikH.C. Wainwright
H.C. Wainwright
$41$53
Buy
2.91%
Upside
Reiterated
06/23/25
Cidara Therapeutics price target raised to $53 from $41 at H.C. WainwrightCidara Therapeutics price target raised to $53 from $41 at H.C. Wainwright
RBC Capital Analyst forecast on CDTX
Brian AbrahamsRBC Capital
RBC Capital
$35$75
Buy
45.63%
Upside
Reiterated
06/23/25
Cidara Therapeutics price target raised to $75 from $35 at RBC CapitalCidara Therapeutics price target raised to $75 from $35 at RBC Capital
Cantor Fitzgerald Analyst forecast on CDTX
Eric Schmidt FCACantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
06/10/25
Cidara Therapeutics (CDTX) Receives a Buy from Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cidara Therapeutics

1 Month
xxx
Success Rate
7/8 ratings generated profit
88%
Average Return
+26.91%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 87.50% of your transactions generating a profit, with an average return of +26.91% per trade.
3 Months
xxx
Success Rate
6/8 ratings generated profit
75%
Average Return
+20.34%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +20.34% per trade.
1 Year
Stephen BrozakWBB Securities
Success Rate
5/8 ratings generated profit
63%
Average Return
+28.65%
reiterated a buy rating 24 days ago
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +28.65% per trade.
2 Years
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+30.00%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +30.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CDTX Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
4
5
13
15
13
Buy
4
4
5
9
9
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
9
18
24
23
In the current month, CDTX has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CDTX average Analyst price target in the past 3 months is 59.17.
Each month's total comprises the sum of three months' worth of ratings.

CDTX Financial Forecast

CDTX Earnings Forecast

Next quarter’s earnings estimate for CDTX is -$1.95 with a range of -$3.03 to -$1.19. The previous quarter’s EPS was -$1.66. CDTX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year CDTX has Outperformed its overall industry.
Next quarter’s earnings estimate for CDTX is -$1.95 with a range of -$3.03 to -$1.19. The previous quarter’s EPS was -$1.66. CDTX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year CDTX has Outperformed its overall industry.

CDTX Sales Forecast

Next quarter’s sales forecast for CDTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CDTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CDTX has Preformed in-line its overall industry.
Next quarter’s sales forecast for CDTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CDTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CDTX has Preformed in-line its overall industry.

CDTX Stock Forecast FAQ

What is CDTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Cidara Therapeutics’s 12-month average price target is 59.17.
    What is CDTX’s upside potential, based on the analysts’ average price target?
    Cidara Therapeutics has 14.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CDTX a Buy, Sell or Hold?
          Cidara Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Cidara Therapeutics’s price target?
            The average price target for Cidara Therapeutics is 59.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $75.00 ,the lowest forecast is $45.00. The average price target represents 14.89% Increase from the current price of $51.5.
              What do analysts say about Cidara Therapeutics?
              Cidara Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of CDTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis